A Phase 3 interventional study of Hydromorphone and Nonprotocolized in Acute Pain, sponsored by Montefiore Medical Center. Completed at 1 site in United States. Open to participants aged 21 Years to 64 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-04-05.
Sponsored by Montefiore Medical Center · Phase 3, Interventional, and Treatment
Patients treated with protocolized pain management (1 mg of IV hydromorphone followed by an additional 1 mg IV hydromorphone if the patient wants more) will have better pain relief and no more adverse events than patients receiving non-protocolized pain management.
876 studies on the registry are indexed under Acute Pain; 154 are open to participants now.
This study's enrollment of 224 is above the median of 90 across 732 interventional studies indexed under Acute Pain.
Browse Acute Pain studies →Montefiore Medical Center is the lead sponsor of 402 studies on the registry; 70 are open to participants now.
Of its 81 completed or terminated interventional studies of FDA-regulated products, 73 (90%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
C02 measurement greater than 46: In accordance with a similar study (04-12-360), four subsets of patients will have their CO2 measured using a handheld capnometer prior to enrollment in the study. If the CO2 measurement is greater than 46, then the patient will be excluded from the study. The 4 subsets are as follows:
1mg IV hydromorphone followed by an additional 1mg at 15 minutes if the patient answer "yes" to the question, "Do you want more pain medication?"
Drug: Hydromorphone
An IV opioid the type and dose of which will be determined by the treating clincian
Drug: Nonprotocolized
Hydromorphone 1mg IV, followed by an optional dose of 1mg IV hydromorphone 15 minutes
Also known as: Dilaudid
An IV opioid the type and dose of which will be determined by the treating clinician
Also known as: Usual Care
Patient Reported Change in Pain Intensity From Initial Administration of Analgesics (Baseline) to 60 Minutes Post-baseline.
Pain intensity is rated on the numerical rating scale (NRS), measured in integer units from 0 ("no pain") to 10 ("worst pain imaginable"). The change in pain intensity subtracts the NRS score given by the patient 60 minutes after treatment was administered from the baseline NRS score (before treatment in the Emergency Department).
Time frame: 60 minutes
| Milestone | Protocolized | Nonprotocolized |
|---|---|---|
| Started | 112 | 112 |
| Completed | 112 | 112 |
| Not completed | 0 | 0 |
Pain intensity is rated on the numerical rating scale (NRS), measured in integer units from 0 ("no pain") to 10 ("worst pain imaginable"). The change in pain intensity subtracts the NRS score given by the patient 60 minutes after treatment was administered from the baseline NRS score (before treatment in the Emergency Department).
| units on a scale | Protocolized | Nonprotocolized |
|---|---|---|
| Patient Reported Change in Pain Intensity From Initial Administration of Analgesics (Baseline) to 60 Minutes Post-baseline. | 5.5 ± 2.9 | 4.5 ± 3.0 |
Pain intensity is rated on the numerical rating scale (NRS), measured in integer units from 0 ("no pain") to 10 ("worst pain imaginable"). The change in pain intensity subtracts the NRS score given by the patient 60 minutes after treatment was administered from the baseline score (before treatment in the Emergency Department).
| units on a scale | Protocolized | Nonprotocolized |
|---|---|---|
| Change in Numerical Rating Scale (NRS) Scores Among Patients Who Received 1 Dose of Intravenous (IV) Hydromorphone | 6.1 ± 4.0 | 4.5 ± 3.1 |
Pain intensity is rated on the numerical rating scale (NRS), measured in integer units from 0 ("no pain") to 10 ("worst pain imaginable"). The change in pain intensity subtracts the NRS score given by the patient 60 minutes after treatment was administered from the baseline score (before treatment in the Emergency Department).
| units on a scale | Protocolized | Nonprotocolized |
|---|---|---|
| Change in Numerical Rating Scale (NRS) Scores Among Patients Who Received 2 Doses of Intravenous (IV) Hydromorphone | 4.0 ± 3.2 | 4.3 ± 3.3 |
Pain intensity is rated on the numerical rating scale (NRS), measured in integer units from 0 ("no pain") to 10 ("worst pain imaginable"). The change in pain intensity subtracts the NRS score given by the patient 60 minutes after treatment was administered from the baseline score (before treatment in the Emergency Department). The comparison of hydromorphone to morphine is due to the wide use of morphine for pain management in the Emergency Department setting and the comparison of the two opioids in previous studies.
| units on a scale | Protocolized | Nonprotocolized |
|---|---|---|
| Change in Numerical Rating Scale (NRS) Scores Among Patients in the Protocolized Group vs Those in the Physician Driven Group Who Received Only Intravenous (IV) Morphine | 5.6 ± 3.2 | 4.4 ± 2.8 |
Collected over 60 minutes after the last dose of opioids was given. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Protocolized | 0/108 (0%) | 0/108 (0%) | 33/108 (30.6%) |
| Nonprotocolized | 0/110 (0%) | 0/110 (0%) | 27/110 (24.5%) |
| Event | Protocolized | Nonprotocolized |
|---|---|---|
| NauseaGastrointestinal disorders | 11/64 | 5/56 |
| Pulse rate <60 beats/minVascular disorders | 4/106 | 9/106 |
| PruritusSkin and subcutaneous tissue disorders | 7/108 | 4/110 |
| VomitingGastrointestinal disorders | 3/64 | 1/56 |
| Oxygen saturation 90-94%Respiratory, thoracic and mediastinal disorders | 5/108 | 2/110 |
| Systolic blood pressure <90 mmHgVascular disorders | 2/108 | 3/108 |
| Oxygen saturation <90%Respiratory, thoracic and mediastinal disorders | 0/108 | 2/110 |
| Respiratory rate <12 breaths /minRespiratory, thoracic and mediastinal disorders | 1/108 | 1/110 |
The difference between the number of participants who enrolled and completed the study and the number of participants analyzed is due to missing outcome data. There were 4 missing data from the Protocolized group, and 2 missing data from the Nonprotocolized group, for a total of 6 patients. These 6 patients were excluded from the analysis.
| Age, Continuous(years) | Protocolized | Nonprotocolized | Total |
|---|---|---|---|
| Mean | 40 ± 11 | 41 ± 12 | 41 ± 12 |
| Sex: Female, Male(Participants) | Protocolized | Nonprotocolized | Total |
|---|---|---|---|
| Female | 66 | 75 | 141 |
| Male | 42 | 35 | 77 |
| Race/Ethnicity, Customized(Participants) | Protocolized | Nonprotocolized | Total |
|---|---|---|---|
| Black | 25 | 34 | 59 |
| White | 9 | 8 | 17 |
| Hispanic | 72 | 66 | 138 |
| Other | 2 | 2 | 4 |
| Region of Enrollment(Participants) | Protocolized | Nonprotocolized | Total |
|---|---|---|---|
| United States | 108 | 110 | 218 |
| Weight(lbs) | Protocolized | Nonprotocolized | Total |
|---|---|---|---|
| Mean | 179 ± 52 | 177 ± 49 | 178 ± 51 |
| Location of Pain(Participants) | Protocolized | Nonprotocolized | Total |
|---|---|---|---|
| Abdomen | 59 | 73 | 132 |
| Other | 49 | 37 | 86 |
| Pain Intensity(Participants) | Protocolized | Nonprotocolized | Total |
|---|---|---|---|
| 3-7 | 8 | 15 | 23 |
| 8 | 22 | 26 | 48 |
| 9 | 11 | 14 | 25 |
| 10 | 67 | 55 | 122 |
| Nausea/vomiting(Participants) | Protocolized | Nonprotocolized | Total |
|---|---|---|---|
| Count of participants | 44 | 54 | 98 |
1 further baseline measures are reported on the registry.
This study is completed, as verified in Apr 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Montefiore Medical Center